Aldose reductase inhibitors and the complications of diabetes mellitus.
Tomlinson
D R
DR
Department of Pharmacology, Queen Mary and Westfield College, London, UK.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002386:Cataract / Q000188:drug therapy* / Q000378:metabolism; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000201:enzymology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000201:enzymology; D009281:Naphthalenes / Q000627:therapeutic use*; D051381:Rats
D009281:Naphthalenes; C040550:tolrestat; D000449:Aldehyde Reductase